polyphor.com

Website review polyphor.com

 Generated on November 01 2024 14:01 PM

Old data? UPDATE !

The score is 50/100

Download PDF Version

SEO Content

Title

Spexis – Delivering Continuous Hope for Rare Disease and Cancer Patients

Length : 72

Ideally, your title should contain between 10 and 70 characters (spaces included). Use this free tool to calculate text length.

Description

Length : 0

Very bad. We haven't found meta description on your page. Use this free online meta tags generator to create description.

Keywords

Very bad. We haven't found meta keywords on your page. Use this free online meta tags generator to create keywords.

Og Meta Properties

Good, your page take advantage of Og Properties.

Property Content
title Home - Spexis
type article
url https://spexisbio.com/
site_name Spexis
image https://spexisbio.com/wp-content/uploads/2022/03/Spexis-Home-2022-03-23.jpg

Headings

H1 H2 H3 H4 H5 H6
3 3 7 4 0 0
  • [H1] Home
  • [H1] Generating hope for rare disease & oncology patients
  • [H1] Pipeline
  • [H2] Rare Disease
  • [H2] Oncology
  • [H2] Macrocycle Platform
  • [H3] Latest news
  • [H3] Inhaled Murepavadin
  • [H3] Lonodelestat (external link)
  • [H3] Balixafortide
  • [H3] OMPTA BamA / LptA Programs, Others
  • [H3] Interact with us
  • [H3]  
  • [H4] Spexis granted definitive moratorium status until 25 November 2024, subject to monthly progress report obligations, and which can be potentially extended at the request of the administrators.
  • [H4] Spexis expects that audit of its 2023 financials will not be completed by 31 July 2024, provides status update relating to the Company’s moratorium and changes to its Executive Committee.
  • [H4] Inhaled murepavadin is a novel-class inhaled antibiotic specifically targeting Pseudomonas aeruginosa
  • [H4] Balixafortide is a macrocyclic CXCR4 inhibitor which has been studied in clinical trials involving over 500 subjects

Images

We found 2 images on this web page.

Good, most or all of your images have alt attributes.

Text/HTML Ratio

Ratio : 3%

This page's ratio of text to HTML code is below 15 percent, this means that your website probably needs more text content.

Flash

Perfect, no Flash content has been detected on this page.

Iframe

Great, there are no Iframes detected on this page.

URL Rewrite

Good. Your links looks friendly!

Underscores in the URLs

Perfect! No underscores detected in your URLs.

In-page links

We found a total of 29 links including 0 link(s) to files

Anchor Type Juice
Inhaled Murepavadin External Passing Juice
Balixafortide External Passing Juice
Lonodelestat (external) External Passing Juice
Corporate Governance* External Passing Juice
Reporting* External Passing Juice
Corporate Presentation External Passing Juice
Share Information External Passing Juice
Media Releases External Passing Juice
Ad-hoc Releases External Passing Juice
Calendar External Passing Juice
Contact External Passing Juice
News Internal Passing Juice
Pipeline Internal Passing Juice
Partnering Internal Passing Juice
About us Internal Passing Juice
Spexis granted definitive moratorium status until 25 November 2024, subject to monthly progress report obligations, and which can be potentially extended at the request of the administrators. External Passing Juice
Spexis expects that audit of its 2023 financials will not be completed by 31 July 2024, provides status update relating to the Company’s moratorium and changes to its Executive Committee. External Passing Juice
Inhaled Murepavadin Internal Passing Juice
Inhaled murepavadin is a novel-class inhaled antibiotic specifically targeting Pseudomonas aeruginosa Internal Passing Juice
Balixafortide Internal Passing Juice
Balixafortide is a macrocyclic CXCR4 inhibitor which has been studied in clinical trials involving over 500 subjects Internal Passing Juice
OMPTA BamA / LptA Programs, Others External Passing Juice
Partnering External Passing Juice
Join our team External Passing Juice
Spexis Ltd., External Passing Juice
Disclaimer Internal Passing Juice
Privacy Rules Internal Passing Juice
Disclosure Internal Passing Juice
Find out more. External Passing Juice

SEO Keywords

Keywords Cloud

committee partnering news join team get all see interact spexis

Keywords Consistency

Keyword Content Title Keywords Description Headings
news 3
spexis 2
partnering 2
committee 1
see 1

Usability

Url

Domain : polyphor.com

Length : 12

Favicon

Great, your website has a favicon.

Printability

Great. We have found a Print-Friendly CSS.

Language

Good. Your declared language is en.

Dublin Core

This page does not take advantage of Dublin Core.

Document

Doctype

HTML 5

Encoding

Perfect. Your declared charset is UTF-8.

W3C Validity

Errors : 12

Warnings : 98

Email Privacy

Warning! At least one email address has been found in the plain text. Use free antispam protector to hide email from spammers.

Deprecated HTML

Great! We haven't found deprecated HTML tags in your HTML.

Speed Tips

Excellent, your website doesn't use nested tables.
Too bad, your website is using inline styles.
Too bad, your website has too many CSS files (more than 4).
Too bad, your website has too many JS files (more than 6).
Perfect, your website takes advantage of gzip.

Mobile

Mobile Optimization

Apple Icon
Meta Viewport Tag
Flash content

Optimization

XML Sitemap

Great, your website has an XML sitemap.

https://spexisbio.com/wp-sitemap.xml

Robots.txt

http://polyphor.com/robots.txt

Great, your website has a robots.txt file.

Analytics

Missing

We didn't detect an analytics tool installed on this website.

Web analytics let you measure visitor activity on your website. You should have at least one analytics tool installed, but It can also be good to install a second in order to cross-check the data.

PageSpeed Insights

Device
Categories

Website Review

Website Review is a free SEO tool which provides you content analysis of the website.